Long-term Natural History of Dry Eye Disease from the Patient's Perspective

被引:56
作者
Lienert, Jeffrey P. [1 ]
Tarko, Laura [2 ]
Uchino, Miki [3 ]
Christen, William G. [4 ]
Schaumberg, Debra A. [1 ,4 ,5 ]
机构
[1] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[2] Boston Univ, Sch Publ Hlth, Boston, MA USA
[3] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan
[4] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02115 USA
[5] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr,Ctr Translat Med, Salt Lake City, UT USA
基金
美国国家卫生研究院;
关键词
QUALITY-OF-LIFE; OCULAR-SURFACE; PREVALENCE; PHYSICIANS; IMPACT; INDEX;
D O I
10.1016/j.ophtha.2015.10.011
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To describe the natural history of dry eye disease (DED), which chronically affects millions of people in the United States. Design: This study is based on the Women's Health Study and Physicians' Health Studies, and uses questionnaires and medical records. Participants: A total of 398 men and 386 women who reported a diagnosis of DED and responded to a questionnaire about change in disease since diagnosis. Methods: Three subscales were developed using factor analysis of questionnaire responses: ocular surface symptoms, vision-related symptoms, and social impact. We examined correlates of worsening on each subscale, obtained medical records from a subset of 261 study participants, and examined changes in clinical signs of DED over time. Main Outcome Measures: Worsening in ocular surface symptoms, vision-related symptoms, and social impact plus clinical signs. Results: The average duration of DED of 10.5 years (standard deviation, 9.5 years). Worsening was reported by 24% for ocular surface symptoms, 29% for vision-related symptoms, and 10% for social impact. Factors associated with worsening on at least 2 of 3 subscales included a previous report of severe DED symptoms (odds ratio [OR], 2.17 for ocular surface symptoms; OR, 2.35 for vision-related symptoms), spending >$20 per month on DED treatments (OR, 1.80 for ocular surface symptoms; OR, 1.99 for vision-related symptoms), history of blepharitis or meibomian gland dysfunction (MGD) (OR, 1.57 for vision-related symptoms; OR, 2.12 for social impact), and use of systemic beta-blockers (OR, 1.62 for ocular surface symptoms; OR, 1.84 for vision-related symptoms; OR, 1.86 for the social impact of DED). Presence of corneal staining based on review of medical records was associated with use of level 2 or higher DED treatments (OR, 1.54; confidence interval [CI], 1.01-2.36), a previous report of severe DED symptoms (OR, 1.79; CI, 1.07-3.00), having a tear break-up test performed (OR, 2.73; CI, 1.72-4.36), and having blepharitis or MGD (OR, 0.59; CI, 0.35-0.98). Conclusions: A proportion of patients with DED experience worsening over time, tending to report with more severe symptoms earlier in the disease. Forthcoming data on the natural history of DED from prospective studies should help clarify some of the limitations of this retrospective study. (C) 2016 by the American Academy of Ophthalmology.
引用
收藏
页码:425 / 433
页数:9
相关论文
共 21 条
[1]   Dry Eye Disease Treatment: A Systematic Review of Published Trials and a Critical Appraisal of Therapeutic Strategies [J].
Alves, Monica ;
Fonseca, Ellen Carrara ;
Alves, Milena Freitas ;
Malki, Leonardo Tannus ;
Arruda, Gustavo Viani ;
Reinach, Peter S. ;
Rocha, Eduardo Melani .
OCULAR SURFACE, 2013, 11 (03) :181-192
[2]   Comparison of Two Questionnaires for Dry Eye Symptom Assessment The Ocular Surface Disease Index and the Symptom Assessment in Dry Eye [J].
Amparo, Francisco ;
Schaumberg, Debra A. ;
Dana, Reza .
OPHTHALMOLOGY, 2015, 122 (07) :1498-1503
[3]  
Apostol Silvia, 2003, Oftalmologia, V59, P28
[4]   Adverse effects of topical antiglaucoma drugs on the ocular surface [J].
Arici, MK ;
Arici, DS ;
Topalkara, A ;
Güler, C .
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2000, 28 (02) :113-117
[5]  
Buring JE., 1992, J MYOCARDIAL ISCHEMI, V4, P27
[6]   Back to basics [J].
Foulks, Gary N. .
OCULAR SURFACE, 2007, 5 (01) :5-5
[7]   Quality of life measurement: bibliographic study of patient assessed health outcome measures [J].
Garratt, AN ;
Schmidt, L ;
Mackintosh, A ;
Fitzpatrick, R .
BMJ-BRITISH MEDICAL JOURNAL, 2002, 324 (7351) :1417-1419
[8]   A RANDOMIZED TRIAL OF ASPIRIN AND BETA-CAROTENE AMONG UNITED-STATES PHYSICIANS [J].
HENNEKENS, CH ;
EBERLEIN, K .
PREVENTIVE MEDICINE, 1985, 14 (02) :165-168
[9]  
Jaanus S D, 1992, Optom Clin, V2, P73
[10]   Impact of dry eye syndrome on vision-related quality of life [J].
Miljanovic, Biljana ;
Dana, Reza ;
Sullivan, David A. ;
Schaumberg, Debra A. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2007, 143 (03) :409-415